Subcutaneous versus Intravenous Bortezomib Administration for Multiple Myeloma Patients：a Meta-analysis

作     者：Shi-dai MU Li-sha AI You QIN Yu HU 牟时代;艾利莎;秦铀;胡豫

作者机构：Institute of Hematology Union Hospital Tongji Medical College Huazhong University of Science and Technology Wuhan 430022 China Cancer Center Union Hospital Tongji Medical College Huazhong University of Science and Technology Wuhan 430022 China 

出 版 物：《Journal of Huazhong University of Science and Technology(Medical Sciences)》 (华中科技大学学报（医学英德文版）)

年 卷 期：2018年第38卷第1期

页      面：43-50页

核心收录：

学科分类：1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学] 

基　　金：supported by grants from National Natural Science Foundation of China(No.81500172 and No.81202962) Integrated Innovative Team for Major Human Diseases Program of Tongji Medical College,HUST Clinical Research Physician Program of Tongji Medical College,HUST 

主　　题：bortezomib multiple myeloma meta-analysis subcutaneous administration 

摘      要：Bortezomib,the first potent therapeutic proteasome inhibitor,has been suggested as a standard care in patients with newly diagnosed and relapsed multiple myeloma（MM）.However,evidence bearing on the efficacy and safety of subcutaneous（SC） versus intravenous（IV） administration of bortezomib for MM patients is *** controlled trials（RCTs） and observational studies were enrolled in our meta-analysis to investigate the efficacy and safety of bortezomib via SC *** administration on MM *** trials with a total of 2575 patients with MM（SC,n=1191;IV,n=1384） were included in our *** were no significant differences between these two arms regarding overall response rate（ORR）,complete response（CR）,or very good partial response（VGPR）.The pooled RRs for rate of adverse events（AEs）,such as thrombocytopenia and bortezomib-induced peripheral neuropathy（BIPN）,were 0.79（95% CI：0.68–0.92） and 0.63（95% CI：0.51–0.79）,***,there was much more largely decreased incidence of grade 3 and higher thrombocytopenia and BIPN in bortezomib SC administration than IV *** general,alternative SC administration should be considered instead of IV administration in use of bortezomib for patients with MM.